Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epinastine vs Alesion LX vs olopatadine in allergic conjunctivitis
CTR20234212Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of epinastine in allergic conjunctivitis (AC), sponsored by Santen Pharmaceutical. Started Dec 2023; status: completed.
02
Drugs
epinastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on CTR20234212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234212.